Equillium (FRA:0FY) Research & Development : €34.61 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Equillium's Research & Development for the three months ended in Dec. 2024 was €6.99 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €34.61 Mil.

Equillium Research & Development Historical Data

The historical data trend for Equillium's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Research & Development Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

15.93

23.35

35.44

33.97

35.74

Equillium Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Research & Development	Get a 7-Day Free Trial															8.42	8.96	10.04	8.62	6.99

Equillium Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €34.61 Mil.

Equillium (FRA:0FY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Equillium Research & Development Related Terms

Thank you for viewing the detailed overview of Equillium's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

EQ:USA 0A4D:UK

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Headlines

No Headlines